Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria... Show more
The Moving Average Convergence Divergence (MACD) for CLVLF turned positive on September 17, 2025. Looking at past instances where CLVLF's MACD turned positive, the stock continued to rise in of 35 cases over the following month. The odds of a continued upward trend are .
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CLVLF's RSI Indicator exited the oversold zone, of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on September 17, 2025. You may want to consider a long position or call options on CLVLF as a result. In of 52 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
CLVLF moved above its 50-day moving average on September 16, 2025 date and that indicates a change from a downward trend to an upward trend.
The 50-day moving average for CLVLF moved above the 200-day moving average on August 26, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
CLVLF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 142 cases where CLVLF Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 10-day moving average for CLVLF crossed bearishly below the 50-day moving average on September 12, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.489) is normal, around the industry mean (19.637). P/E Ratio (16.656) is within average values for comparable stocks, (53.583). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.168). Dividend Yield (0.004) settles around the average of (0.044) among similar stocks. P/S Ratio (6.341) is also within normal values, averaging (331.570).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CLVLF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLVLF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology